SLC6A3 and Cognitive impairment: In the earlier studies, we demonstrated that a novel quinazoline structure-based compound, SRI-32743, normalizes Tat-induced inhibition of DAT and reduces both cocaine reward enhancement and cognitive impairment in inducible Tat transgenic mice [23].